文献速递药物不良反应与药物警戒

全球药物警戒数据库中致死性药物不良反应的十年回顾分析

Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database.
PubMed 文献 · Br J Clin Pharmacol · 2021-04-24

该研究对VigiBase中2010至2019年由医生报告的成人致死性药物不良反应进行回顾性描述分析,纳入3 250 967例报告,其中43 685例为致死性。致死性报告多见于75岁以上患者,涉及药物类别以抗肿瘤/免疫调节药最多,其次为神经系统药和心脏药;报告风险在男性、美洲地区及≥65岁患者中更高。

要点

  • 致死性药物不良反应报告多见于75岁以上患者,男性及≥65岁患者报告风险更高。
  • 涉及药物类别以抗肿瘤/免疫调节药最常见,其次为神经系统药和心脏药。
  • 报告风险存在显著地域差异,美洲地区较高,且各大洲和国家间存在重要差异。

核心结论

  • 近10年大型药物警戒数据库中致死性药物不良反应约占全部药物不良反应的1%略多。
  • 致死性报告更多见于男性、65岁以上患者,且以抗肿瘤/免疫调节药为主。
  • 研究首次揭示了致死性药物不良反应在大洲和国家间存在重要差异。

研究设计与样本

  • 研究为回顾性分析,数据来源于世界卫生组织药物警戒数据库VigiBase。
  • 分析方法为描述性分析,考察年龄、性别和可疑药物;采用不成比例分析计算报告比值比及其95%置信区间,比较性别、年龄和洲际间的报告差异。

主要发现

  • 致死性药物不良反应主要报告于75岁以上患者。
  • 最常涉及的3类药物依次为抗肿瘤/免疫调节药、神经系统药和心脏药。
  • 涉及最多的3个单药为denosumab、lenalidomide和thalidomide,且随年龄、性别、大洲和国家有显著差异。
  • 致死性药物不良反应的报告风险在男性、美洲地区及≥65岁患者中更高。

临床怎么用

  • 临床应关注高龄(尤其75岁以上)及男性患者中致死性药物不良反应的风险信号。
  • 对使用抗肿瘤/免疫调节药、神经系统药和心脏药的患者,尤其需加强不良反应监测与预警。
  • 应结合地域差异认识致死性药物不良反应的报告特征,优化本地药物警戒实践。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Adverse drug reactions (ADRs) are important causes of death. However, the main involved drugs are relatively unknown. The present study was performed to characterise death-related drugs recorded in a large pharmacovigilance database during the last 10 years. METHODS: A retrospective analysis of VigiBase, the World Health Organization pharmacovigilance database, was performed investigating fatal ADRs registered between 1 January 2010 and 31 December 2019 in male and female patients aged ≥18 years and reported by physicians. Analyses were descriptive investigating age, sex and suspected drugs. Differences in reporting according to sex, age and continents were investigated using disproportionality analysis with calculation of reporting odds ratio and its 95% confidence interval. RESULTS: Among the 23 millions ADRs recorded in VigiBase, 3 250 967 were included with 43 685 fatal. They were reported mainly in patients older than 75 years. The 3 most frequently involved drug classes were antineoplastic/immunomodulating drugs followed by nervous system and cardiac drugs. The top 3 individual drugs were denosumab, lenalidomide and thalidomide with marked differences according to age, sex, continents and countries. The risk of reporting fatal ADRs was higher in males, in the Americas and in patients ≥65 years. CONCLUSION: Fatal ADRs registered in a large pharmacovigilance database during the last 10 years correspond to just over 1% of the total number of ADRs. They occurred more in males, after 65 years and with antineoplastic/immunomodulating drugs in general. Our study also highlighted, for the first time, important differences in fatal ADRs between continents and countries.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Montastruc JL, Lafaurie M, de Canecaude C, et al. Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database. Br J Clin Pharmacol. 2021. PMID: 33837554. doi:10.1111/bcp.14851

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。